ADMA - Company ID 0001368514
The table below shows ADMA BIOLOGICS, INC.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $141.10M | $124.39M | $114.49M | $134.22M | $121.98M | $114.80M |
| Cost of revenue | $41.19M | $38.12M | $33.74M | $58.60M | $54.76M | $53.70M |
| Gross profit | $99.92M | $86.28M | $80.75M | $75.63M | $67.23M | $61.10M |
| R&D | $4.49M | $6.01M | $2.60M | $1.53M | $1.03M | $826.00K |
ADMA BIOLOGICS, INC. reported annual revenue of $510.17M for fiscal year 2025. That is up 19.6% from $426.45M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $10.66M (FY 2016) to $510.17M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $26.55M | $26.74M | $26.74M | $21.78M | $22.21M | $24.08M |
| Operating income | $67.76M | $52.45M | $58.27M | $51.01M | $42.80M | $34.88M |
| Income tax | $15.72M | $12.41M | $11.80M | $11.09M | $5.88M | $6.55M |
| Net income | $49.88M | $37.82M | $45.33M | $36.43M | $34.22M | $26.90M |
| EPS (diluted) | $0.22 | $0.16 | $0.19 | $0.15 | $0.14 | $0.11 |